Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$33.00

0.14 (0.43%)

06:25
10/04/16
10/04
06:25
10/04/16
06:25

AstraZeneca says Brilinta did not meet primary endpoint in EUCLID trial

AstraZeneca announced top-line results from the EUCLID trial. Brilinta did not demonstrate a benefit over clopidogrel in a symptomatic peripheral artery disease patient population and therefore did not meet the primary endpoint of the trial.The EUCLID trial included 13,885 patients in 28 countries and is the largest cardiovascular outcomes trial to date conducted exclusively in symptomatic patients with PAD. It evaluated the treatment of Brilinta 90mg tablets twice daily versus clopidogrel 75mg once daily for the prevention of atherothrombotic events. The primary endpoint of the trial was the time to first occurrence of any such event. Based on preliminary analyses, safety data is consistent with the known safety profile of Brilinta. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: "The proven benefits of Brilinta in acute coronary syndrome and post-myocardial infarction patients are established and remain unchanged. We are disappointed that the EUCLID trial results showed Brilinta did not demonstrate a benefit over clopidogrel in this specific symptomatic PAD population." Full results from the EUCLID trial are expected to be presented at the American Heart Association Scientific Sessions in New Orleans, Louisiana in November 2016.

  • 07

    Oct

  • 16

    Nov

AZN AstraZeneca
$33.00

0.14 (0.43%)

09/12/16
09/12/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pandora (P) upgraded to Buy from Neutral at SunTrust with analyst Robert Peck saying he thinks that a new interactive offering by the company could raise its contribution profit by 4%-9% and that the Street's 2017 estimates for the company "seem conservative." The analyst added that he thinks it's "very possible" that Pandora will be acquired. 2. AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies with analyst Jeffrey Holford saying the company's MYSTIC oncology study could drive 39% share upside if successful. 3. Apache (APA) and upgraded to Overweight from Neutral at Atlantic Equities and to Peer Perform from Underperform at Wolfe Research. 4. Philip Morris (PM) upgraded to Conviction Buy from Neutral at Goldman with analyst Judy Hong saying she is increasingly bullish on the prospects of Next Generation Products and expects them to contribute 5%-6% of earnings by 2020. 5. Wal-Mart (WMT) upgraded to Outperform from Market Perform at Cowen with analysts led by Oliver Chen saying price investments, integration of physical and digital, and the Jet acquisitions position the company to regain its dominance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/16
EXAN
09/13/16
DOWNGRADE
EXAN
Neutral
AstraZeneca downgraded to Neutral from Outperform at Exane BNP Paribas
09/23/16
PIPR
09/23/16
INITIATION
PIPR
Overweight
AstraZeneca initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started AstraZeneca with an Overweight rating and GBP 60 price target.
09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

KMPH

KemPharm

$3.45

0.05 (1.47%)

08:24
06/28/17
06/28
08:24
06/28/17
08:24
Initiation
KemPharm initiated  »

KemPharm initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMPH

KemPharm

$3.45

0.05 (1.47%)

08:23
06/28/17
06/28
08:23
06/28/17
08:23
Initiation
KemPharm initiated  »

KemPharm initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOW

ServiceNow

$106.77

-1.58 (-1.46%)

08:22
06/28/17
06/28
08:22
06/28/17
08:22
Recommendations
ServiceNow analyst commentary  »

ServiceNow shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJT

DJ Transportation Average

08:20
06/28/17
06/28
08:20
06/28/17
08:20
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$220.28

-0.16 (-0.07%)

08:20
06/28/17
06/28
08:20
06/28/17
08:20
Recommendations
Goldman Sachs analyst commentary  »

Goldman Sachs price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 17

    Oct

$DJU

DJ Utility Average

08:20
06/28/17
06/28
08:20
06/28/17
08:20
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

08:20
06/28/17
06/28
08:20
06/28/17
08:20
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$168.95

-1.025697 (-0.60%)

08:20
06/28/17
06/28
08:20
06/28/17
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:20
06/28/17
06/28
08:20
06/28/17
08:20
General news
U.S. advance goods trade deficit preview: »

U.S. advance goods trade…

XLK

Technology Select Sector SPDR

$55.08

-0.92 (-1.64%)

08:19
06/28/17
06/28
08:19
06/28/17
08:19
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$64.14

-0.1 (-0.16%)

08:19
06/28/17
06/28
08:19
06/28/17
08:19
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$35.09

-0.91 (-2.53%)

08:19
06/28/17
06/28
08:19
06/28/17
08:19
Earnings
Chemours raises 2017 adjusted EBITDA view to 'above $1.25B' »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$89.13

-0.71 (-0.79%)

08:19
06/28/17
06/28
08:19
06/28/17
08:19
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$53.68

-0.33 (-0.61%)

08:19
06/28/17
06/28
08:19
06/28/17
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$52.97

-0.6 (-1.12%)

08:18
06/28/17
06/28
08:18
06/28/17
08:18
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$55.23

-0.48 (-0.86%)

08:18
06/28/17
06/28
08:18
06/28/17
08:18
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDXG

Interpace Diagnostics

$0.85

-0.043 (-4.82%)

, AET

Aetna

08:18
06/28/17
06/28
08:18
06/28/17
08:18
Hot Stocks
Interpace Diagnostics announces national contract with Aetna »

Interpace Diagnostics…

IDXG

Interpace Diagnostics

$0.85

-0.043 (-4.82%)

AET

Aetna

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBIO

Catalyst Biosciences

$4.47

-0.07 (-1.54%)

08:18
06/28/17
06/28
08:18
06/28/17
08:18
Hot Stocks
Catalyst granted orphan product designation for hemophilia B candidate in Europe »

Catalyst Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

XLV

Health Care Select Sector SPDR

$79.66

-0.73 (-0.91%)

08:18
06/28/17
06/28
08:18
06/28/17
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$139.84

-1.24 (-0.88%)

08:18
06/28/17
06/28
08:18
06/28/17
08:18
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIA

Diamonds Fund ETF

$212.93

-0.94 (-0.44%)

08:17
06/28/17
06/28
08:17
06/28/17
08:17
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$241.33

-1.96 (-0.81%)

08:17
06/28/17
06/28
08:17
06/28/17
08:17
Technical Analysis
SPDR S&P 500 ETF Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$24.14

0.12 (0.50%)

08:17
06/28/17
06/28
08:17
06/28/17
08:17
Technical Analysis
Financial Select Sector: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMH

Market Vectors Semiconductor

$82.90

-2.44 (-2.86%)

08:16
06/28/17
06/28
08:16
06/28/17
08:16
Technical Analysis
Market Vectors Semiconductor: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGVT

Ingevity

$53.69

-0.86 (-1.58%)

08:16
06/28/17
06/28
08:16
06/28/17
08:16
Hot Stocks
Ingevity to construct activated carbon extrustion plant in China »

Ingevity Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.